Corporate / M&A

IP / IT

Windward Bio_we_640x140

Homburger News

Share-Image Teamplate Deals-and-Cases

On January 10, 2025, Windward Bio Group AG, a Swiss-based private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, announced its launch with a USD 200 m series A financing from lead investors OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and co-investors SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal bioVenture Partners. Windward Bio has entered into an agreement to license WIN378, a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP), from Kelun-Biotech and Harbour BioMed for global rights, excepting China and select smaller markets in Asia.
Proceeds from the financing will be used to develop a phase 2-ready, long-acting anti-TSLP antibody with best-in-class potential in asthma and chronic obstructive pulmonary disease (COPD).
Homburger AG advises Windward Bio on its set-up and financing. The Homburger team comprises Andreas Müller, Margrit Marti, Oliver Kneubühl, Kaiyan Yeo, Eric Huber, Jonas Stähli, Rebecca Sigrist and Carolina Rodriguez (all Corporate / M&amp;A), Stefan Oesterhelt and Juliette Buob (both Tax) and Luca Dal Molin (IP / IT).

Homburger advises Windward Bio on its USD 200 m Series A Financing

Regulatory

Employment and Executive Compensation

novo-nordisk_web_640x140

On December 18, 2024, Novo Nordisk announced that it has successfully completed its USD 11 bn acquisition of three manufacturing sites from Novo Holdings A/S. The completion follows the finalization of Novo Holdings&#8217; acquisition of Catalent, Inc., a global contract development and manufacturing organization. The three acquired sites are specialized in the sterile filling of drugs and are located in Anagni (Italy), Brussels (Belgium) and Bloomington IN (USA).
Novo Nordisk is a leading global healthcare company headquartered in Denmark. Its purpose is to drive change to defeat serious chronic diseases, built upon its heritage in diabetes.
Catalent is a global contract development and manufacturing organization headquartered in Somerset, New Jersey. The company has over 50 global sites and employs more than 18,000 people.
A Homburger team comprising Andreas Müller, Anna Peter, Simone Schmid, Bianca Nedwed, Florian Bruggisser and Maria Braun (all Corporate / M&amp;A), Allegra Arnold, Meret Horisberger and Harun Cetin (all Regulatory), Jeremy Reichlin (Employment) as well as Reto Heuberger, Juliette Buob and Philipp Stiegeler (all Tax) advised Novo Nordisk on the transaction.

Homburger advises on Novo Nordisk / Novo Holdings / Catalent transaction

Capital Markets

Competition

Financing and Investment Products

Real Estate

On October 16, 2024, Liberty Global Ltd. (NASDAQ: LBTYA, LBTYB and LBTYK) and Sunrise Communications AG (Sunrise) announced the key dates of the spin-off of Sunrise from Liberty Global. After the spin-off, Sunrise, which is Switzerland&#8217;s largest private telecommunications provider, will be an independent, separate publicly traded Swiss company.
As part of the spin-off, Liberty Global shareholders will receive Sunrise Class A shares and Sunrise Class B shares in the form of Sunrise Class A ADSs and Sunrise Class B ADSs. The Sunrise Class A shares will be listed on the SIX Swiss Exchange (SIX) and the Sunrise Class A ADSs will be listed on the Nasdaq Global Select Market (NASDAQ). The spin-off is subject to approval by Liberty Global&#8217;s shareholders. The first day of trading on the NASDAQ and the SIX is scheduled for November 13 and 15, 2024, respectively.
Homburger AG acts as Swiss counsel to Liberty Global and Sunrise. The Homburger team is led by Daniel Daeniker and Daniel (Danny) Häusermann and includes, among others, Carlo Sulser, Patrick Schmidt, Michael Lüchinger, Marilena Balthasar, Felix Beltle and Paula Delissen (all Corporate / M&amp;A, Capital Markets), Stefan Oesterhelt, Laetitia Fracheboud, Juliette Buob and Tanja Niederer (all Tax), Andreas Müller, Jeremy Reichlin and Daniel Bötticher (all Employment and Executive Compensation), Richard Stäuber and Christoph Grüninger (all Competition, Regulatory), Gabriel Kasper (IP / IT), Sarah Fasel (Financing and Investment Products) and Daniel Junginger (Real Estate).

Homburger advises Liberty Global and Sunrise on the Spin-off and Listing of Sunrise on the SIX and NASDAQ

Juliette
Buob

Homburger advises Windward Bio on its USD 200 m Series A Financing

Homburger advises on Novo Nordisk / Novo Holdings / Catalent transaction

Homburger advises Liberty Global and Sunrise on the Spin-off and Listing of Sunrise on the SIX and NASDAQ

Join the Team

Juliette Buob

Career

Languages

Teams

JulietteBuob

Homburger advises Windward Bio on its USD 200 m Series A Financing

Homburger advises on Novo Nordisk / Novo Holdings / Catalent transaction

Homburger advises Liberty Global and Sunrise on the Spin-off and Listing of Sunrise on the SIX and NASDAQ

Join the Team

Juliette Buob

Career

Languages

Teams

Juliette
Buob